End-of-day quote
Korea S.E.
03:30:00 13/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1,821
KRW
|
-1.03%
|
|
-0.60%
|
-26.57%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,78,785
|
2,01,714
|
2,61,315
|
1,85,849
|
1,75,309
|
1,25,738
|
Enterprise Value (EV)
1 |
3,26,267
|
2,12,975
|
2,79,717
|
1,99,670
|
1,85,923
|
1,34,782
|
P/E ratio
|
-36.8
x
|
140
x
|
-40.5
x
|
212
x
|
127
x
|
-3.36
x
|
Yield
|
0.89%
|
1.24%
|
0.95%
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.04
x
|
1.97
x
|
2.52
x
|
1.84
x
|
1.71
x
|
1.21
x
|
EV / Revenue
|
3.56
x
|
2.08
x
|
2.69
x
|
1.98
x
|
1.81
x
|
1.29
x
|
EV / EBITDA
|
111
x
|
55.2
x
|
102
x
|
28.4
x
|
25.2
x
|
16.2
x
|
EV / FCF
|
39.9
x
|
71
x
|
82.8
x
|
26.4
x
|
28.1
x
|
27
x
|
FCF Yield
|
2.51%
|
1.41%
|
1.21%
|
3.79%
|
3.56%
|
3.7%
|
Price to Book
|
8.32
x
|
3.05
x
|
4.64
x
|
3.35
x
|
3.13
x
|
7.5
x
|
Nbr of stocks (in thousands)
|
50,502
|
50,502
|
50,502
|
50,717
|
50,709
|
50,701
|
Reference price
2 |
5,520
|
3,994
|
5,174
|
3,664
|
3,457
|
2,480
|
Announcement Date
|
21/03/19
|
25/03/20
|
18/03/21
|
21/03/22
|
21/03/23
|
18/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
91,776
|
1,02,531
|
1,03,803
|
1,00,966
|
1,02,710
|
1,04,235
|
EBITDA
1 |
2,943
|
3,859
|
2,740
|
7,041
|
7,366
|
8,296
|
EBIT
1 |
577.3
|
1,146
|
-553.6
|
3,426
|
4,287
|
5,628
|
Operating Margin
|
0.63%
|
1.12%
|
-0.53%
|
3.39%
|
4.17%
|
5.4%
|
Earnings before Tax (EBT)
1 |
-4,735
|
2,618
|
-6,407
|
2,572
|
3,025
|
-35,597
|
Net income
1 |
-7,509
|
1,442
|
-6,446
|
883.8
|
1,400
|
-37,357
|
Net margin
|
-8.18%
|
1.41%
|
-6.21%
|
0.88%
|
1.36%
|
-35.84%
|
EPS
2 |
-149.9
|
28.55
|
-127.6
|
17.28
|
27.21
|
-737.1
|
Free Cash Flow
1 |
8,182
|
3,001
|
3,376
|
7,565
|
6,612
|
4,991
|
FCF margin
|
8.91%
|
2.93%
|
3.25%
|
7.49%
|
6.44%
|
4.79%
|
FCF Conversion (EBITDA)
|
278%
|
77.76%
|
123.21%
|
107.43%
|
89.77%
|
60.17%
|
FCF Conversion (Net income)
|
-
|
208.1%
|
-
|
855.95%
|
472.31%
|
-
|
Dividend per Share
2 |
49.36
|
49.36
|
49.36
|
-
|
-
|
-
|
Announcement Date
|
21/03/19
|
25/03/20
|
18/03/21
|
21/03/22
|
21/03/23
|
18/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
47,481
|
11,261
|
18,402
|
13,821
|
10,613
|
9,044
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
16.13
x
|
2.918
x
|
6.715
x
|
1.963
x
|
1.441
x
|
1.09
x
|
Free Cash Flow
1 |
8,182
|
3,001
|
3,376
|
7,565
|
6,612
|
4,991
|
ROE (net income / shareholders' equity)
|
-21.5%
|
2.91%
|
-10.6%
|
1.5%
|
2.49%
|
-104%
|
ROA (Net income/ Total Assets)
|
0.31%
|
0.58%
|
-0.3%
|
2.27%
|
2.88%
|
4.4%
|
Assets
1 |
-24,19,815
|
2,47,757
|
21,72,443
|
38,866
|
48,615
|
-8,48,163
|
Book Value Per Share
2 |
663.0
|
1,310
|
1,115
|
1,093
|
1,104
|
331.0
|
Cash Flow per Share
2 |
28.80
|
586.0
|
62.10
|
19.90
|
57.10
|
375.0
|
Capex
1 |
1,064
|
843
|
1,161
|
894
|
1,440
|
1,044
|
Capex / Sales
|
1.16%
|
0.82%
|
1.12%
|
0.89%
|
1.4%
|
1%
|
Announcement Date
|
21/03/19
|
25/03/20
|
18/03/21
|
21/03/22
|
21/03/23
|
18/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -26.57% | 6.75Cr | | +7.22% | 7.25TCr | | +13.69% | 911.43Cr | | -11.75% | 507.42Cr | | +59.61% | 501.29Cr | | +2.62% | 384.98Cr | | -17.54% | 245.97Cr | | +21.35% | 244.06Cr | | -27.82% | 226.26Cr | | +25.13% | 227.16Cr |
Specialty & Advanced Pharmaceuticals
|